Skip to main content

DeLIVER DeLIVER: A Prospective, Single-Arm, Multi-Center Study of the Metavention Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT04285554

DeLIVER: A Prospective, Single-Arm, Multi-Center Study of the Metavention Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

Associated Conditions

Diabetes-Care Delivery

Principal Investigator

Sponsor

Metavention

You have been invited to join A Prospective, Single-Arm, Multi-Center Study of the Metavention Integrated Radio Frequency Nerve Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects (The DeLIVER U.S. Study). This is because you have been diagnosed with Type 2 Diabetes (T2D) and Non-alcoholic Fatty Liver Disease (NAFLD). This research study is testing a new investigational treatment for T2D using a study device called the Metavention Integrated Radio Frequency Nerve Denervation System (iRF System), which is intended to scar or disrupt the nerve activity to the liver. The study device is investigational and not approved by the Food and Drug Administration (FDA) in the United States for your medical condition.

This study is currently enrolling.